Novel ATP-competitive kinesin spindle protein inhibitors

  • J Med Chem. 2007 Oct 4;50(20):4939-52. doi: 10.1021/jm070435y.
Cynthia A Parrish  1 ,  Nicholas D Adams ,  Kurt R Auger ,  Joelle L Burgess ,  Jeffrey D Carson ,  Amita M Chaudhari ,  Robert A Copeland ,  Melody A Diamond ,  Carla A Donatelli ,  Kevin J Duffy ,  Leo F Faucette ,  Jeffrey T Finer ,  William F Huffman ,  Erin D Hugger ,  Jeffrey R Jackson ,  Steven D Knight ,  Lusong Luo ,  Michael L Moore ,  Ken A Newlander ,  Lance H Ridgers ,  Roman Sakowicz ,  Antony N Shaw ,  Chiu-Mei M Sung ,  David Sutton ,  Kenneth W Wood ,  Shu-Yun Zhang ,  Michael N Zimmerman ,  Dashyant Dhanak
Affiliations
  • 1. Department of Medicinal Chemistry, Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA. [email protected]
PMID: 17725339 DOI: 10.1021/jm070435y
Abstract

Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during Mitosis that is present only in proliferating cells, has become a novel and attractive Anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile as compared to the known loop 5 (L5) allosteric KSP inhibitors that are currently under clinical evaluation. Optimization of this series led to the identification of biphenyl sulfamide 20, a potent KSP inhibitor with in vitro antiproliferative activity against human cells with either wild-type KSP (HCT116) or mutant KSP (HCT116 D130V). In a murine xenograft model with HCT116 D130V tumors, 20 showed significant antitumor activity following intraperitoneal dosing, providing in vivo proof-of-principle of the efficacy of an ATP-competitive KSP inhibitor versus tumors that are resistant to the Other known KSP inhibitors.

Products